Clinical Breast Cancer

1

Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer

Jasgit C. Sachdev, Mohammad Jahanzeb

Journal:

Year:

2012

Language:

english

File:

PDF, 710 KB

english, 2012

2

Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions

M. Pegram, J. Liao

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 385 KB

english, 2012

3

Predicting the Likelihood of Nonsentinel Lymph Node Metastases in Triple Negative Breast Cancer Patients With a Positive Sentinel Lymph Node: Turkish Federation of Breast Disease Associations Protocol MF09-01

Serdar Ozbas, Vahit Ozmen, Abdullah Igci, Mahmut Muslumanoglu, Beyza Ozcinar, Mujdat Balkan, Fatih Aydogan, Tulay Canda, Omer Harmancioglu, Erol Aksaz, Bahadir M. Gulluoglu, Munire Kayahan, Cihangir O

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 289 KB

english, 2012

4

A Hidden Breast Lump Covered by Nipple Appendices in a Patient with von Recklinghausen Disease: A Case Report and Review of the Literature

Yidong Zhou, Bo Pan, Feng Mao, Qingli Zhu, Zhen Huo, Hongyan Wang, Feng Cai, Zhiyong Liang, Changjun Wang, Yanna Zhang, Qiang Sun

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 3.93 MB

english, 2012

5

Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy

Alwin Jeyakumar, Jillian DiPenta, Stephanie Snow, Daniel Rayson, Kara Thompson, Chris Theriault, Tallal Younis

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 294 KB

english, 2012

6

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

Antonio Llombart, Antonio Frassoldati, Outi Paija, Harm Peter Sleeboom, Guy Jerusalem, Jeroen Mebis, Ines Deleu, Joel Miller, Nora Schenk, Patrick Neven

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 437 KB

english, 2012

7

A Case of Late Breast Cancer Metastases to Both Suprarenal Glands 28 Years After Mastectomy

Tomasz Banasiewicz, Łukasz Krokowicz, Maciej Biczysko, Małgorzata Janicka-Jedyńska, Andrzej Pławski, Jacek Paszkowski, Piotr Gronek, Bolesław Stawny, Michał Drews

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 955 KB

english, 2012

8

Pleomorphic Lobular Carcinoma in Situ: Treatment Options for a New Pathologic Entity

Lauren Murray, Michael Reintgen, Kurt Akman, Charles Cox, John Cox, Douglas Reintgen, Harvey Greenberg, Verne Vrcel

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 1.64 MB

english, 2012

9

Correction

Journal:

Clinical Breast Cancer

Year:

2012

File:

PDF, 48 KB

2012

10

Comparative Acute Toxicity from Whole Breast Irradiation Using 3-Week Accelerated Schedule With Concomitant Boost and the 6.5-Week Conventional Schedule With Sequential Boost for Early-Stage Breast Cancer

Manjeet Chadha, Dan Vongtama, Patricia Friedmann, Celina Parris, Susan K. Boolbol, Rudolph Woode, Louis B. Harrison

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 1.24 MB

english, 2012

11

Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits?

Michael S. Ewer, Ming Yang, Aman U. Buzdar

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 148 KB

english, 2012

12

Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer

Seigo Nakamura, Masashi Ando, Norikazu Masuda, Kenjiro Aogi, Hiroyo Ino, Hiroji Iwata, Yutaka Tokuda, Naohito Yamamoto, Hiroi Kasai, Masahiko Takeuchi, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosum

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 401 KB

english, 2012

13

Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials

Maria Rosa Strada, Raffaella Palumbo, Antonio Bernardo, Alberto Riccardi, Cristina Teragni, Guido Poggi, Mara Frascaroli, Alessio Amatu, Benedetta Montagna, Federico Sottotetti, Barbara Tagliaferri, G

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 423 KB

english, 2012

14

Editorial Board/Masthead

Journal:

Clinical Breast Cancer

Year:

2012

Language:

english

File:

PDF, 68 KB

english, 2012

15

Volume 12; Issue 1

Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer

Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions

Predicting the Likelihood of Nonsentinel Lymph Node Metastases in Triple Negative Breast Cancer Patients With a Positive Sentinel Lymph Node: Turkish Federation of Breast Disease Associations Protocol MF09-01

A Hidden Breast Lump Covered by Nipple Appendices in a Patient with von Recklinghausen Disease: A Case Report and Review of the Literature

Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

A Case of Late Breast Cancer Metastases to Both Suprarenal Glands 28 Years After Mastectomy

Pleomorphic Lobular Carcinoma in Situ: Treatment Options for a New Pathologic Entity

Correction

Comparative Acute Toxicity from Whole Breast Irradiation Using 3-Week Accelerated Schedule With Concomitant Boost and the 6.5-Week Conventional Schedule With Sequential Boost for Early-Stage Breast Cancer

Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits?

Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer

Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials

Editorial Board/Masthead

Table of Contents